At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 64 enrolled
Drug / intervention
TG4050drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Trial Evaluating a Mutanome-directed Immunotherapy in Patients With High Grade Serous Carcinoma (HGSC) of the Ovary, Fallopian Tube or Peritoneum.
In Brief
A Phase 1 clinical trial evaluating TG4050 for Ovarian Carcinoma and 2 related conditions. Completed, enrolled 64 participants across 6 sites in 2 countries.
Detailed Summary
This is a multicenter, open-label, single arm phase I study evaluating the safety and tolerability as well as some activity parameters of TG4050 in patients with ovarian, fallopian or peritoneal serous carcinoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesFrance, United States
Collaborators--
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
First PostedFeb 2019
Enrollment StartDec 2019
Primary CompletionOct 2024
TodayJul 2026
First PostedFeb 15, 2019
Enrollment StartDec 9, 2019
Primary CompletionOct 8, 2024
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 7.4 years ago
Interventions
TG4050drug
Subcutaneous injections weekly for the first 6 weeks and then every 3 weeks.